Clinical trial
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive…
NCT00113256 · Astex Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00113256 |
|---|---|
| Title | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer |
| Official title | Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Rubitecan |
| Enrollment | 39 |
| Start date | Feb 1, 2005 |
| Primary completion | Feb 1, 2006 |
| First posted | Jun 7, 2005 |
| Last update posted | Aug 2, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: